HYTN Announces Sale and Distribution of GMP Cannabis Products in the UK
HYTN Innovations has successfully completed its first export of cannabis products to the UK's 4C LABS, following their recent GMP designation. The initial shipment of 43.75 kilograms of cannabis flower for medical use has been paid in full and is now available to UK patients through the country's regulated medical sales model.
Following this achievement, HYTN has received additional orders for over 500 kilograms of products for immediate manufacture, demonstrating strong market demand for their GMP-certified cannabis-based pharmaceuticals in the international market. The company's products are manufactured under Good Manufacturing Practices (GMP) standards to meet international regulatory requirements.
HYTN Innovations ha completato con successo la sua prima esportazione di prodotti a base di cannabis verso il 4C LABS del Regno Unito, dopo aver ricevuto di recente la designazione GMP. La spedizione iniziale di 43,75 chilogrammi di fiori di cannabis per uso medico è stata pagata completamente ed è ora disponibile per i pazienti britannici attraverso il modello di vendita medica regolamentata del paese.
Dopo questo risultato, HYTN ha ricevuto ulteriori ordini per oltre 500 chilogrammi di prodotti per una fabbricazione immediata, dimostrando una forte domanda di mercato per i loro farmaci a base di cannabis certificati GMP nel mercato internazionale. I prodotti dell’azienda sono realizzati secondo gli standard delle Buone Pratiche di Fabbricazione (GMP) per soddisfare i requisiti normativi internazionali.
HYTN Innovations ha completado con éxito su primera exportación de productos de cannabis a 4C LABS del Reino Unido, tras recibir recientemente la designación GMP. El envío inicial de 43,75 kilogramos de flores de cannabis para uso médico ha sido pagado por completo y ahora está disponible para los pacientes del Reino Unido a través del modelo de ventas médicas reguladas del país.
Después de este logro, HYTN ha recibido pedidos adicionales por más de 500 kilogramos de productos para fabricación inmediata, lo que demuestra una fuerte demanda en el mercado por sus productos farmacéuticos a base de cannabis certificados GMP en el mercado internacional. Los productos de la compañía se fabrican bajo estándares de Buenas Prácticas de Fabricación (GMP) para cumplir con los requisitos regulatorios internacionales.
HYTN Innovations는 최근 GMP 인증을 받은 후, 영국의 4C LABS에 대해 최초의 대마초 제품 수출을 성공적으로 완료했습니다. 의료용 대마꽃 43.75킬로그램의 초기 배송이 전액 지급되었으며, 현재 영국의 규제된 의료 판매 모델을 통해 영국 환자들에게 제공되고 있습니다.
이 성과에 이어, HYTN은 국제 시장에서 GMP 인증을 받은 대마초 기반 제약 제품에 대한 강한 시장 수요를 보여주며 즉각적인 제조를 위한 500킬로그램 이상의 추가 주문을 받았습니다. 회사의 제품은 국제 규제 요구 사항을 충족하기 위해 우수 제조 관리 기준(GMP) 아래에서 제조됩니다.
HYTN Innovations a réussi à compléter sa première exportation de produits à base de cannabis vers le 4C LABS du Royaume-Uni, à la suite de leur récente désignation GMP. La première expédition de 43,75 kilogrammes de fleurs de cannabis à usage médical a été entièrement payée et est maintenant disponible pour les patients britanniques via le modèle de vente médicale réglementé du pays.
À la suite de cette réalisation, HYTN a reçu des commandes supplémentaires pour plus de 500 kilogrammes de produits pour une fabrication immédiate, démontrant une forte demande sur le marché pour leurs produits pharmaceutiques à base de cannabis certifiés GMP sur le marché international. Les produits de l'entreprise sont fabriqués selon des normes de Bonnes Pratiques de Fabrication (BPF) pour répondre aux exigences réglementaires internationales.
HYTN Innovations hat erfolgreich seine erste Exportlieferung von Cannabisprodukten an die 4C LABS im Vereinigten Königreich abgeschlossen, nachdem sie kürzlich die GMP-Zertifizierung erhalten haben. Die erste Lieferung von 43,75 Kilogramm Cannabisblüten für medizinische Zwecke wurde vollständig bezahlt und ist nun für britische Patienten über das regulierte medizinische Verkaufsmodell des Landes verfügbar.
Nach diesem Erfolg hat HYTN zusätzliche Bestellungen von über 500 Kilogramm Produkten für die sofortige Herstellung erhalten, was die starke Marktnachfrage nach ihren GMP-zertifizierten, cannabisbasierten Pharmazeutika auf dem internationalen Markt demonstriert. Die Produkte des Unternehmens werden gemäß den Richtlinien für gute Herstellungspraxis (GMP) hergestellt, um internationalen regulatorischen Anforderungen gerecht zu werden.
- Successfully completed first international GMP cannabis export to UK
- Initial order of 43.75kg fully paid and delivered
- Secured additional orders for 500kg of products
- Achieved GMP certification enabling international market access
- None.
Products now accessible to UK patients, with over 500 kilograms of additional orders in production
VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or "the Company"), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its successful export of cannabis to the United Kingdom’s 4C LABS. This announcement follows the news from November 28, 2024, that the Company received its first international order for products manufactured under its recently awarded Good Manufacturing Practices (GMP) designation.
The completed shipment of this first order includes the successful export, import, final packaging and release for supply of 43.75 kilograms of cannabis flower for medical use. The company confirms that this initial order has been paid in full and that the products shipped are now available to patients across the UK through the country's regulated medical sales model.
Following this initial success, HYTN has received orders for immediate manufacture totaling over 500 kilograms of additional products, underscoring the growing demand for its premium cannabis-based pharmaceuticals in the international market.
"The fulfillment of our first order to 4C LABS and the subsequent substantial orders highlight the trust and confidence our partners place in our products and the strength and efficiency of our GMP standards," said Jason Broome, Chief Operations Officer of HYTN. "We are committed to stabilizing international supply lines and ensuring that our products meet or exceed the regulatory requirements of international markets."
HYTN's products are manufactured under Good Manufacturing Practices (GMP) standards, ensuring they meet the stringent quality requirements of international markets. This milestone aligns with HYTN's strategic goal to expand its global footprint and provide high-quality cannabis products to patients worldwide.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.
About 4C LABS Ltd.
4C LABS is a Canadian-based Medical Cannabis company which is building a vertically integrated, quality-driven infrastructure for procuring and delivering premium medical cannabis products to the UK, EU and other international regulated markets.
4C LABS focuses on launching products in regulated markets with an additional focus on research and development of new and innovative plant based therapeutic finished product forms that can be introduced to the 4C catalogue.
About Good Manufacturing Practices
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.
For more information contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the receipt of additional purchase orders, the Company’s ability to fulfill the same, and the Company’s expanded abilities to export its products globally, including to the UK. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company’s business include, among other things: the Company’s inability to fulfill purchase orders; the Company's failure to generate sufficient cash flow from operations to meet its current and future obligations; the Company's failure to access sources of debt and equity capital; changes to the regulatory framework within which the Company operates; competitive factors, pricing pressures, and supply and demand in the Company’s industry; and general economic and business conditions. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.
FAQ
How much cannabis did HYTN (HYTNF) export to the UK in its first shipment?
What is the size of HYTN's (HYTNF) additional orders following the UK export?
When did HYTN (HYTNF) complete its first UK cannabis export?
How are HYTN's (HYTNF) cannabis products distributed in the UK?
What certification enables HYTN (HYTNF) to export cannabis internationally?
